PMID- 34919673
OWN - NLM
STAT- MEDLINE
DCOM- 20240208
LR  - 20240208
IS  - 1462-0332 (Electronic)
IS  - 1462-0324 (Linking)
VI  - 61
IP  - 9
DP  - 2022 Aug 30
TI  - Tolerance of glucocorticoids in giant cell arteritis: a study of patient-reported 
      adverse events.
PG  - 3567-3575
LID - 10.1093/rheumatology/keab921 [doi]
AB  - OBJECTIVE: To assess patients' self-reported glucocorticoid (GC)-related adverse 
      events (AEs) in a GCA population. METHODS: A questionnaire was sent to the 100 
      patients most recently diagnosed with GCA in a tertiary centre. This 
      questionnaire included open- and close-ended questions on the disease and GC 
      effects. Eight primary AE areas were analysed: cardiovascular, metabolic, muscle, 
      cognitive and psychologic, bone, cutaneous and hairiness, infective and visual 
      complications. Including derivative subitems from preceding areas, a total of 18 
      GC-related AEs were analysed separately and according to GC duration. RESULTS: 
      Ninety patients were analysed and 89 (99%) reported at least one GC-related AE 
      [median 6 (range 1-11)]. Cognitive and psychological changes, primarily insomnia 
      (72%), affected 90% of patients. Cutaneous changes and muscle loss affected 70% 
      of patients, with frequent impairment of physical autonomy (P = 0.007) associated 
      with this event. Metabolic issues, especially weight gain (40%) and diabetes 
      mellitus (20%), affected 49% of patients. Conversely, vision troubles and bone 
      fractures were mentioned by 42% and 9% of patients, respectively, and more 
      frequently in patients who received GCs for >18 months (P = 0.01 and P = 0.007, 
      respectively). Cardiovascular changes and infections affected 30% and 26% of 
      patients, respectively. CONCLUSION: This real-life study of GC tolerance assessed 
      using a self-evaluation provides pragmatic and updated data reminding us that GC 
      tolerance remains more noteworthy than ever. This study suggests carefully 
      monitoring GC-related AEs during follow-up and encourages GC-sparing strategies 
      in some patients.
CI  - (c) The Author(s) 2021. Published by Oxford University Press on behalf of the 
      British Society for Rheumatology. All rights reserved. For permissions, please 
      email: journals.permissions@oup.com.
FAU - de Boysson, Hubert
AU  - de Boysson H
AUID- ORCID: 0000-0001-9083-8365
AD  - Department of Internal Medicine, Caen University Hospital.
AD  - Caen University-Normandie, Caen, France.
FAU - Barakat, Clivia
AU  - Barakat C
AD  - Department of Internal Medicine, Caen University Hospital.
FAU - Dumont, Anael
AU  - Dumont A
AUID- ORCID: 0000-0003-1105-7662
AD  - Department of Internal Medicine, Caen University Hospital.
AD  - Caen University-Normandie, Caen, France.
FAU - Boutemy, Jonathan
AU  - Boutemy J
AD  - Department of Internal Medicine, Caen University Hospital.
FAU - Martin Silva, Nicolas
AU  - Martin Silva N
AD  - Department of Internal Medicine, Caen University Hospital.
FAU - Maigne, Gwenola
AU  - Maigne G
AD  - Department of Internal Medicine, Caen University Hospital.
FAU - Nguyen, Alexandre
AU  - Nguyen A
AD  - Department of Internal Medicine, Caen University Hospital.
AD  - Caen University-Normandie, Caen, France.
FAU - Lavergne, Amandine
AU  - Lavergne A
AD  - Department of Internal Medicine, Caen University Hospital.
FAU - Castan, Paul
AU  - Castan P
AD  - Department of Internal Medicine, Caen University Hospital.
FAU - Gallou, Sophie
AU  - Gallou S
AD  - Department of Internal Medicine, Caen University Hospital.
FAU - Sultan, Audrey
AU  - Sultan A
AD  - Department of Internal Medicine, Caen University Hospital.
FAU - Deshayes, Samuel
AU  - Deshayes S
AD  - Department of Internal Medicine, Caen University Hospital.
AD  - Caen University-Normandie, Caen, France.
FAU - Aouba, Achille
AU  - Aouba A
AD  - Department of Internal Medicine, Caen University Hospital.
AD  - Caen University-Normandie, Caen, France.
LA  - eng
PT  - Journal Article
PL  - England
TA  - Rheumatology (Oxford)
JT  - Rheumatology (Oxford, England)
JID - 100883501
RN  - 0 (Glucocorticoids)
SB  - IM
MH  - Humans
MH  - *Giant Cell Arteritis/diagnosis/drug therapy
MH  - *Glucocorticoids/adverse effects/toxicity
MH  - Patient Reported Outcome Measures
MH  - Skin
OTO - NOTNLM
OT  - GCA
OT  - adverse events
OT  - glucocorticoids
OT  - questionnaire
OT  - tolerance
EDAT- 2021/12/18 06:00
MHDA- 2022/09/09 06:00
CRDT- 2021/12/17 17:22
PHST- 2021/08/02 00:00 [received]
PHST- 2021/12/05 00:00 [revised]
PHST- 2021/12/18 06:00 [pubmed]
PHST- 2022/09/09 06:00 [medline]
PHST- 2021/12/17 17:22 [entrez]
AID - 6468637 [pii]
AID - 10.1093/rheumatology/keab921 [doi]
PST - ppublish
SO  - Rheumatology (Oxford). 2022 Aug 30;61(9):3567-3575. doi: 
      10.1093/rheumatology/keab921.